MRI, Efficacy, and Safety of Tolebrutinib in Highly Active Disease: 2-Year Data from Phase 2b Long-term Safety Study

被引：0
|
作者：
Fox, R. [1 ]
Oh, J. [2 ]
Arnold, D. [3 ]
Syed, S. [4 ]
Xu, Z. [5 ]
Turner, T. [4 ]
Traboulsee, A. [6 ]
Reich, D. [7 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH USA
[2] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[3] McGill Univ, NeuroRx Res & Montreal Neurol Inst, Montreal, PQ, Canada
[4] Sanofi, Cambridge, MA USA
[5] Sanofi, Bridgewater, MA USA
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-318
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [1] MRI, efficacy, and safety of tolebrutinib in patients with highly active disease (HAD): 2-year data from the phase 2b Long-term safety (LTS) Study
    Fox, R. J.
    Oh, J.
    Arnold, D. L.
    Syed, S.
    Xu, Z.
    Turner, T. J.
    Traboulsee, A.
    Reich, D. S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 331 - 331
  • [2] MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study
    Fox, Robert
    Oh, Jiwon
    Arnold, Douglas
    Syed, Sana
    Xu, Zhixing
    Turner, Timothy
    Traboulsee, Anthony
    Reich, Daniel
    NEUROLOGY, 2023, 100 (17)
  • [3] Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study
    Syed, Sana
    Yonkers, Nicole
    LaGanke, Christopher
    Honeycutt, William David
    Traboulsee, Anthony
    Wynn, Daniel
    Wray, Sibyl
    Wallstroem, Erik
    Dukovic, Deborah
    Turner, Timothy
    NEUROLOGY, 2021, 96 (15)
  • [4] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [5] BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
    Van der Heijde, D.
    Deodhar, A.
    Gensler, L. S.
    Poddubnyy, D.
    Kivitz, A.
    Dougados, M.
    De Peyrecave, N.
    Oortgiesen, M.
    Vaux, T.
    Fleurinck, C.
    Baraliakos, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 332 - 333
  • [6] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results
    Reich, Daniel
    Traboulsee, Anthony
    Syed, Sana
    Xu, Zhixing
    Turner, Timothy
    Arnold, Douglas
    NEUROLOGY, 2023, 100 (17)
  • [7] MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Reich, D. S.
    Traboulsee, A.
    Syed, S.
    Xu, Z.
    Turner, T. J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 334 - 335
  • [8] LONG-TERM SAFETY AND EFFICACY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): 2-YEAR RESULTS FROM A LONG-TERM STUDY
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian
    Levy, Cynthia
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Steinberg, Alexandra
    Xu, Emily
    Yang, Ke
    Choi, Yun-Jung
    Dickinson, Klara
    McWherter, Charles
    HEPATOLOGY, 2021, 74 : 71A - 73A
  • [9] Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
    Baraliakos, Xenofon
    Deodhar, Atul
    van der Heijde, Desiree
    van den Bosch, Filip
    Magrey, Marina
    Maksymowych, Walter P.
    Tomita, Tetsuya
    Xu, Huji
    Massow, Ute
    Vaux, Tom
    Prajapati, Chetan
    Manente, Myriam
    Marten, Alexander
    Gensler, Lianne S.
    RHEUMATOLOGY, 2025,
  • [10] Long-term safety and efficacy of risperidone in children with disruptive behaviour disordersResults of a 2-year extension study
    Magali Reyes
    Roza Olah
    Krisztina Csaba
    Ilse Augustyns
    Marielle Eerdekens
    European Child & Adolescent Psychiatry, 2006, 15 : 97 - 104
12345